The MAX-interacting transcription factor network

Seminars in Cancer Biology

Volumn 16, Issue 4, 2006, Pages 265-274

  Hurlin, Peter J ^a   Huang, Jie ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Mad; MAX; MNT; MXD; MYC

Indexed keywords

BUB1 RELATED PROTEIN; MAX PROTEIN; MYC PROTEIN; PROTEIN MAD1; PROTEIN MAD4; PROTEIN MXD; PROTEIN MXI1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MNT; UNCLASSIFIED DRUG;

CANCER; CANCER INHIBITION; CARCINOGENESIS; CELL FUNCTION; CELL PROLIFERATION; DNA BINDING; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PROTEIN DEFICIENCY; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW;

ANIMALS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; HUMANS; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 33748136848     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2006.07.009     Document Type: Review

References (108)

1. Grandori C., Cowley S.M., James L.P., and Eisenman R.N. The MYC/MAX/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16 (2000) 653-699
2. Stanton B.R., Perkins A.S., Tessarollo L., Sassoon D.A., and Parada L.F. Loss of N-MYC function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev 6 12A (1992) 2235-2247
3. Charron J., Malynn B.A., Fisher P., Stewart V., Jeannotte L., Goff S.P., et al. Embryonic lethality in mice homozygous for a targeted disruption of the N-MYC gene. Genes Dev 6 12A (1992) 2248-2257
4. Davis A.C., Wims M., Spotts G.D., Hann S.R., and Bradley A. A null c-MYC mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev 7 4 (1993) 671-682
5. Sawai S., Shimono A., Wakamatsu Y., Palmes C., Hanaoka K., and Kondoh H. Defects of embryonic organogenesis resulting from targeted disruption of the N-MYC gene in the mouse. Development 117 4 (1993) 1445-1455
6. Moens C.B., Auerbach A.B., Conlon R.A., Joyner A.L., and Rossant J. A targeted mutation reveals a role for N-MYC in branching morphogenesis in the embryonic mouse lung. Genes Dev 6 5 (1992) 691-704
7. Douglas N.C., Jacobs H., Bothwell A.L., and Hayday A.C. Defining the specific physiological requirements for c-MYC in T cell development. Nat Immunol 2 4 (2001) 307-315
8. Trumpp A., Refaeli Y., Oskarsson T., Gasser S., Murphy M., Martin G.R., et al. c-MYC regulates mammalian body size by controlling cell number but not cell size. Nature 414 6865 (2001) 768-773
9. Patel J.H., Loboda A.P., Showe M.K., Showe L.C., and McMahon S.B. Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer 4 7 (2004) 562-568
10. Dang C.V. c-MYC target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19 1 (1999) 1-11
11. Coller H.A., Grandori C., Tamayo P., Colbert T., Lander E.S., Eisenman R.N., et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 97 7 (2000) 3260-3265
12. Guo Q.M., Malek R.L., Kim S., Chiao C., He M., Ruffy M., et al. Identification of c-MYC responsive genes using rat cDNA microarray. Cancer Res 60 21 (2000) 5922-5928
13. Schuhmacher M., Kohlhuber F., Holzel M., Kaiser C., Burtscher H., Jarsch M., et al. The transcriptional program of a human B cell line in response to MYC. Nucleic Acids Res 29 2 (2001) 397-406
14. Menssen A., and Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci USA 99 9 (2002) 6274-6279
15. Shiio Y., Donohoe S., Yi E.C., Goodlett D.R., Aebersold R., and Eisenman R.N. Quantitative proteomic analysis of MYC oncoprotein function. EMBO J 21 (2002) 5088-5096
16. Hulf T., Bellosta P., Furrer M., Steiger D., Svensson D., Barbour A., et al. Whole-genome analysis reveals a strong positional bias of conserved dMYC-dependent E-boxes. Mol Cell Biol 25 9 (2005) 3401-3410
17. Gomez-Roman N., Grandori C., Eisenman R.N., and White R.J. Direct activation of RNA polymerase III transcription by c-MYC. Nature 421 6920 (2003) 290-294
18. Grandori C., Gomez-Roman N., Felton-Edkins Z.A., Ngouenet C., Galloway D.A., Eisenman R.N., et al. c-MYC binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol 7 March (3) (2005) 311-318 [erratum in: Nat Cell Biol 2005;7 (5):531]
19. Arabi A., Wu S., Ridderstrale K., Bierhoff H., Shiue C., Fatyol K., et al. c-MYC associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol 7 3 (2005) 303-310
20. Grewal S.S., Li L., Orian A., Eisenman R.N., and Edgar B.A. MYC-dependent regulation of ribosomal RNA synthesis during Drosophila development. Nat Cell Biol 7 3 (2005) 295-302
21. Oskarsson T., and Trumpp A. The MYC trilogy: lord of RNA polymerases. Nat Cell Biol 7 3 (2005) 215-217
22. White R.J. RNA polymerases I and III, growth control and cancer. Nat Rev Mol Cell Biol 6 1 (2005) 69-78
23. Adhikary S., and Eilers M. Transcriptional regulation and transformation by MYC proteins. Nat Rev Mol Cell Biol 6 8 (2005) 635-645
24. Fernandez P.C., Frank S.R., Wang L., Schroeder M., Liu S., Greene J., et al. Genomic targets of the human c-MYC protein. Genes Dev 17 9 (2003) 1115-1129
25. Orian A., van Steensel B., Delrow J., Bussemaker H.J., Li L., Sawado T., et al. Genomic binding by the Drosophila MYC, MAX, Mad/MNT transcription factor network. Genes Dev 17 9 (2003) 1101-1114
26. Cawley S., Bekiranov S., Ng H.H., Kapranov P., Sekinger E.A., Kampa D., et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 116 4 (2004) 499-509
27. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., and Mendell J.T. c-MYC-regulated microRNAs modulate E2F1 expression. Nature 435 7043 (2005) 839-843
28. Matsumura I., Tanaka H., and Kanakura Y. E2F1 and c-MYC in cell growth and death. Cell Cycle 2 4 (2003) 333-338
29. Pelengaris S., Khan M., and Evan G.I. Suppression of MYC-induced apoptosis in beta cells exposes multiple oncogenic properties of MYC and triggers carcinogenic progression. Cell 109 3 (2002) 321-334
30. Baudino T.A., McKay C., Pendeville-Samain H., Nilsson J.A., Maclean K.H., White E.L., et al. c-MYC is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 16 19 (2002) 2530-2543
31. Pelengaris S., Khan M., and Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2 10 (2002) 764-776
32. Nilsson J.A., and Cleveland J.L. MYC pathways provoking cell suicide and cancer. Oncogene 22 56 (2003) 9007-9021
33. Sears R.C. The life cycle of C-MYC: from synthesis to degradation. Cell Cycle 3 9 (2004) 1133-1137
34. Hemann M.T., Bric A., Teruya-Feldstein J., Herbst A., Nilsson J.A., Cordon-Cardo C., et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436 7052 (2005) 807-811
35. Amati B., Brooks M.W., Levy N., Littlewood T.D., Evan G.I., and Land H. Oncogenic activity of the c-MYC protein requires dimerization with MAX. Cell 72 2 (1993) 233-245
36. Amati B., Dalton S., Brooks M.W., Littlewood T.D., Evan G.I., and Land H. Transcriptional activation by the human c-MYC oncoprotein in yeast requires interaction with MAX. Nature 359 6394 (1992) 423-426
37. Amin C., Wagner A.J., and Hay N. Sequence-specific transcriptional activation by MYC and repression by MAX. Mol Cell Biol 13 1 (1993) 383-390
38. Blackwood E.M., and Eisenman R.N. MAX: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with MYC. Science 251 4998 (1991) 1211-1217
39. Prendergast G.C., Lawe D., and Ziff E.B. Association of Myn, the murine homolog of MAX, with c-MYC stimulates methylation-sensitive DNA binding and ras cotransformation. Cell 65 3 (1991) 395-407
40. Blackwood E.M., Luscher B., and Eisenman R.N. MYC and MAX associate in vivo. Genes Dev 6 1 (1992) 71-80
41. Prochownik E.V., and VanAntwerp M.E. Differential patterns of DNA binding by MYC and MAX proteins. Proc Natl Acad Sci USA 90 3 (1993) 960-964
42. Koskinen P.J., Vastrik I., Makela T.P., Eisenman R.N., and Alitalo K. MAX activity is affected by phosphorylation at two NH2-terminal sites. Cell Growth Differ 5 3 (1994) 313-320
43. Makela T.P., Koskinen P.J., Vastrik I., and Alitalo K. Alternative forms of MAX as enhancers or suppressors of MYC-ras cotransformation. Science 256 5055 (1992) 373-377
44. Vastrik I., Koskinen P.J., Alitalo R., and Makela T.P. Alternative mRNA forms and open reading frames of the MAX gene. Oncogene 8 2 (1993) 503-507
45. Grandori C., Mac J., Siebelt F., Ayer D.E., and Eisenman R.N. MYC-MAX heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo. EMBO J 15 16 (1996) 4344-4357
46. Berkes C.A., and Tapscott S.J. MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol 16 4-5 (2005) 585-595
47. Kato G.J., Lee W.M., Chen L.L., and Dang C.V. MAX: functional domains and interaction with c-MYC. Genes Dev 6 1 (1992) 81-92
48. van Bokhoven H., Celli J., van Reeuwijk J., Rinne T., Glaudemans B., van Beusekom E., et al. MYCN haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome. Nat Genet 37 5 (2005) 465-467
49. Blackwell T.K., Kretzner L., Blackwood E.M., Eisenman R.N., and Weintraub H. Sequence-specific DNA binding by the c-MYC protein. Science 250 4984 (1990) 1149-1151
50. Berberich S.J., and Cole M.D. Casein kinase II inhibits the DNA-binding activity of MAX homodimers but not MYC/MAX heterodimers. Genes Dev 6 2 (1992) 166-176
51. Bousset K., Henriksson M., Luscher-Firzlaff J.M., Litchfield D.W., and Luscher B. Identification of casein kinase II phosphorylation sites in MAX: effects on DNA-binding kinetics of MAX homo- and MYC/MAX heterodimers. Oncogene 8 12 (1993) 3211-3220
52. Sommer A., Bousset K., Kremmer E., Austen M., and Luscher B. Identification and characterization of specific DNA-binding complexes containing members of the MYC/MAX/Mad network of transcriptional regulators. J Biol Chem 273 12 (1998) 6632-6642
53. Ferre-D'Amare A.R., Prendergast G.C., Ziff E.B., and Burley S.K. Recognition by MAX of its cognate DNA through a dimeric b/HLH/Z domain. Nature 363 6424 (1993) 38-45
54. Nair S.K., and Burley S.K. X-ray structures of MYC-MAX and Mad-MAX recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112 2 (2003) 193-205
55. Min S., and Taparowsky E.J. v-MYC, but not MAX, possesses domains that function in both transcription activation and cellular transformation. Oncogene 7 August (8) (1992) 1531-1540
56. Kretzner L., Blackwood E.M., and Eisenman R.N. MYC and MAX proteins possess distinct transcriptional activities. Nature 359 6394 (1992) 426-429
57. Ayer D.E., Kretzner L., and Eisenman R.N. Mad: a heterodimeric partner for MAX that antagonizes MYC transcriptional activity. Cell 72 2 (1993) 211-222
58. Zervos A.S., Gyuris J., and Brent R. Mxi1, a protein that specifically interacts with MAX to bind MYC-MAX recognition sites. Cell 72 2 (1993) 223-232
59. Hurlin P.J., Queva C., Koskinen P.J., Steingrimsson E., Ayer D.E., Copeland N.G., et al. Mad3 and Mad4: novel MAX-interacting transcriptional repressors that suppress c-MYC dependent transformation and are expressed during neural and epidermal differentiation. EMBO J 14 22 (1995) 5646-5659
60. Hurlin P.J., Queva C., and Eisenman R.N. MNT, a novel MAX-interacting protein is coexpressed with MYC in proliferating cells and mediates repression at MYC binding sites. Genes Dev 11 1 (1997) 44-58
61. Meroni G., Reymond A., Alcalay M., Borsani G., Tanigami A., Tonlorenzi R., et al. Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with MAX, binds a non-canonical E box and acts as a transcriptional repressor. EMBO J 16 10 (1997) 2892-2906
62. Hurlin P.J., Steingrimsson E., Copeland N.G., Jenkins N.A., and Eisenman R.N. MGA, a dual-specificity transcription factor that interacts with MAX and contains a T-domain DNA-binding motif. EMBO J 18 24 (1999) 7019-7028
63. Billin A.N., Eilers A.L., Queva C., and Ayer D.E. MLX, a novel MAX-like BHLHZip protein that interacts with the MAX network of transcription factors. J Biol Chem 274 51 (1999) 36344-36350
64. Meroni G., Cairo S., Merla G., Messali S., Brent R., Ballabio A., et al. MLX, a new MAX-like bHLHZip family member: the center stage of a novel transcription factors regulatory pathway?. Oncogene 19 29 (2000) 3266-3277
65. Billin A.N., and Ayer D.E. The Mlx network: evidence for a parallel Max-like transcriptional network that regulates energy metabolism. Curr Top Microbiol Immunol 302 (2006) 255-278
66. Ayer D.E., Lawrence Q.A., and Eisenman R.N. Mad-MAX transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 80 5 (1995) 767-776
67. Schreiber-Agus N., Chin L., Chen K., Torres R., Rao G., Guida P., et al. An amino-terminal domain of Mxi1 mediates anti-MYC oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 80 5 (1995) 777-786
68. Koskinen P.J., Ayer D.E., and Eisenman R.N. Repression of MYC-Ras cotransformation by Mad is mediated by multiple protein-protein interactions. Cell Growth Differ 6 6 (1995) 623-629
69. Vastrik I., Kaipainen A., Penttila T.L., Lymboussakis A., Alitalo R., Parvinen M., et al. Expression of the mad gene during cell differentiation in vivo and its inhibition of cell growth in vitro. J Cell Biol 128 6 (1995) 1197-1208
70. Ayer D.E. Histone deacetylases: transcriptional repression with SINers and NuRDs. Trends Cell Biol 9 5 (1999) 193-198
71. McMahon S.B., Wood M.A., and Cole M.D. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-MYC. Mol Cell Biol 20 January (2) (2000) 556-562
72. Bouchard C., Dittrich O., Kiermaier A., Dohmann K., Menkel A., Eilers M., et al. Regulation of cyclin D2 gene expression by the MYC/MAX/Mad network: MYC-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev 15 16 (2001) 2042-2047
73. Popov N., Wahlstrom T., Hurlin P.J., and Henriksson M. MNT transcriptional repressor is functionally regulated during cell cycle progression. Oncogene 24 56 (2005) 8326-8337
74. Ogawa H., Ishiguro K., Gaubatz S., Livingston D.M., and Nakatani Y. A complex with chromatin modifiers that occupies E2F- and MYC-responsive genes in G0 cells. Science 296 5570 (2002) 1132-1136
75. Sommer A., Waha A., Tonn J., Sorensen N., Hurlin P.J., Eisenman R.N., et al. Analysis of the MAX-binding protein MNT in human medulloblastomas. Int J Cancer 82 6 (1999) 810-816
76. Pulverer B., Sommer A., McArthur G.A., Eisenman R.N., and Luscher B. Analysis of MYC/MAX/Mad network members in adipogenesis: inhibition of the proliferative burst and differentiation by ectopically expressed Mad1. J Cell Physiol 183 3 (2000) 399-410
77. Hurlin P.J., Zhou Z.Q., Toyo-oka K., Ota S., Walker W.L., Hirotsune S., et al. Deletion of MNT leads to disrupted cell cycle control and tumorigenesis. EMBO J 22 18 (2003) 4584-4596
78. Smith A.G., Popov N., Imreh M., Axelson H., and Henriksson M. Expression and DNA-binding activity of MYCN/MAX and MNT/MAX during induced differentiation of human neuroblastoma cells. J Cell Biochem 92 6 (2004) 1282-1295
79. Walker W., Zhou Z.Q., Ota S., Wynshaw-Boris A., and Hurlin P.J. MNT-MAX to MYC-MAX complex switching regulates cell cycle entry. J Cell Biol 169 3 (2005) 405-413
80. Hooker C.W., and Hurlin P.J. Of MYC and MNT. J Cell Sci 119 Pt 2 (2006) 208-216
81. Littlewood T.D., Amati B., Land H., and Evan G.I. MAX and c-MYC/MAX DNA-binding activities in cell extracts. Oncogene 7 9 (1992) 1783-1792
82. Ribon V., Leff T., and Saltiel A.R. c-MYC does not require MAX for transcriptional activity in PC-12 cells. Mol Cell Neurosci 5 3 (1994) 277-282
83. Hopewell R., and Ziff E.B. The nerve growth factor-responsive PC12 cell line does not express the MYC dimerization partner MAX. Mol Cell Biol 15 (1995) 3470-3478
84. Shen-Li H., O'Hagan R.C., Hou Jr. H., Horner II J.W., Lee H.W., and DePinho R.A. Essential role for MAX in early embryonic growth and development. Genes Dev 14 1 (2000) 17-22
85. Mateyak M.K., Obaya A.J., Adachi S., and Sedivy J.M. Phenotypes of c-MYC-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 8 10 (1997) 1039-1048
86. Zanet J., Pibre S., Jacquet C., Ramirez A., de Alboran I.M., and Gandarillas A. Endogenous MYC controls mammalian epidermal cell size, hyperproliferation, endoreplication and stem cell amplification. J Cell Sci 118 Pt 8 (2005) 1693-1704
87. Bettess M.D., Dubois N., Murphy M.J., Dubey C., Roger C., Robine S., et al. c-MYC is required for the formation of intestinal crypts but dispensable for homeostasis of the adult intestinal epithelium. Mol Cell Biol 25 17 (2005) 7868-7878
88. Knoepfler P.S., Cheng P.F., and Eisenman R.N. N-MYC is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 16 20 (2002) 2699-2712
89. Eagle L.R., Yin X., Brothman A.R., Williams B.J., Atkin N.B., and Prochownik E.V. Mutation of the MXI1 gene in prostate cancer. Nat Genet 9 3 (1995) 249-255
90. Prochownik E.V., Eagle Grove L., Deubler D., Zhu X.L., Stephenson R.A., Rohr L.R., et al. Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Genes Chromosomes Cancer 22 4 (1998) 295-304
91. Gray I.C., Phillips S.M., Lee S.J., Neoptolemos J.P., Weissenbach J., and Spurr N.K. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 55 21 (1995) 4800-4803
92. Kawamata N., Park D., Wilczynski S., Yokota J., and Koeffler H.P. Point mutations of the Mxil gene are rare in prostate cancers. Prostate 29 3 (1996) 191-193
93. Edwards S.M., Dearnaley D.P., Ardern-Jones A., Hamoudi R.A., Easton D.F., Ford D., et al., Cancer Research Campaign/British Prostate Group. No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Br J Cancer 76 8 (1997) 992-1000
94. Kuczyk M.A., Serth J., Bokemeyer C., Schwede J., Herrmann R., Machtens S., et al. The MXI1 tumor suppressor gene is not mutated in primary prostate cancer. Oncol Rep 5 1 (1998) 213-216
95. Schreiber-Agus N., Meng Y., Hoang T., Hou Jr. H., Chen K., Greenberg R., et al. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 393 6684 (1998) 483-487
96. Foley K.P., McArthur G.A., Queva C., Hurlin P.J., Soriano P., and Eisenman R.N. Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation. EMBO J 17 3 (1998) 774-785
97. Queva C., McArthur G.A., Iritani B.M., and Eisenman R.N. Targeted deletion of the S-phase-specific MYC antagonist Mad3 sensitizes neuronal and lymphoid cells to radiation-induced apoptosis. Mol Cell Biol 21 3 (2001) 703-712
98. Toyo-oka K., Hirotsune S., Gambello M.J., Zhou Z.Q., Olson L., Rosenfeld M.G., et al. Loss of the MAX-interacting protein MNT in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome. Hum Mol Genet 13 10 (2004) 1057-1067
99. Toyo-oka K., Bowen T.J., Hirotsune S., Li Z., Jain S., Ota S., et al. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression. Cancer Res 66 11 (2006) 5565-5573
100. Dezfouli S., Bakke A., Huang J., Wynshaw-Boris A., and Hurlin P.J. Inflammatory disease and lymphomagenesis caused by deletion of the MYC antagonist MNT in T cells. Mol Cell Biol 26 6 (2006) 2080-2092
101. Nesbit C.E., Tersak J.M., and Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 18 19 (1999) 3004-3016
102. Nilsson J.A., Maclean K.H., Keller U.B., Pendeville H., Baudino T.A., and Cleveland J.L. MNT loss triggers MYC transcription targets, proliferation, apoptosis, and transformation. Mol Cell Biol 24 4 (2004) 1560-1569
103. Loo L.W., Secombe J., Little J.T., Carlos L.S., Yost C., Cheng P.F., et al. The transcriptional repressor dMNT is a regulator of growth in Drosophila melanogaster. Mol Cell Biol 25 16 (2005) 7078-7091
104. Takahashi T., Konishi H., Kozaki K., Osada H., Saji S., Takahashi T., et al. Molecular analysis of a MYC antagonist, ROX/MNT, at 17p13.3 in human lung cancers. Jpn J Cancer Res 89 4 (1998) 347-351
105. Nigro C.L., Venesio T., Reymond A., Meroni G., Alberici P., Cainarca S., et al. The human ROX gene: genomic structure and mutation analysis in human breast tumors. Genomics 49 2 (1998) 275-282
106. Moreno E., and Basler K. dMYC transforms cells into super-competitors. Cell 117 1 (2004) 117-129
107. de la Cova C., Abril M., Bellosta P., Gallant P., and Johnston L.A. Drosophila MYC regulates organ size by inducing cell competition. Cell 117 1 (2004) 107-116
108. Goodliffe J.M., Wieschaus E., and Cole M.D. Polycomb mediates MYC autorepression and its transcriptional control of many loci in Drosophila. Genes Dev 19 24 (2005) 2941-2946